Stock 4502 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Delayed Japan Exchange
Other stock markets
 02:00:00 2024-04-23 am EDT 		5-day change 1st Jan Change
4,122 JPY -0.15% Intraday chart for Takeda Pharmaceutical Company Limited +0.02% +1.68%
Apr. 22 Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs MT
Apr. 22 Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs
MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
CI
Takeda Pharmaceutical Wins US FDA Approval for Subcutaneous Administration of Crohn’s Disease Therapy
MT
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
AQ
Takeda to Hold Fiscal Year 2023 Earnings Call on May 9
AQ
Sector Update: Health Care Stocks Steady Pre-Bell Friday
MT
Takeda Pharmaceutical Receives FDA Approval for Single-Dose Injection Crohn's Disease Treatment
MT
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
BU
U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
CI
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease
DJ
Takeda Pharmaceutical to Issue 2nd Hybrid Bonds in Mid-2024 to Refinance 500 Billion Yen 1st Hybrid Bonds
MT
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
BU
Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited.
CI
Final dividend
FA
Takeda Announces Approval of ADZYNMA Intravenous Injection 1500 in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura
AQ
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
BU
Takeda Pharmaceutical Says Adzynma Gains Approval in Japan to Treat Blood Clotting Disorder
MT
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
BU
Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura
CI
Scilex Settles Patent Dispute With Takeda Pharmaceutical Over Gloperba
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. News Takeda Pharmaceutical Company Limited